Prospective Grant of Co-Exclusive License: Type Alpha Platelet- Derived Growth Factor (PDGF) Receptor Gene

Resumo

This is notice in accordance with 15 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a co-exclusive world-wide license to practice the invention embodies in U.S. Patent Applications SN 07/308,282 and SN 07/915,884, both entitled ``Type Alpha Platelet-Derived Growth Factor Receptor Gene'' to Targeted Genetics Corporation, of Seattle, Washington. The patent rights in this invention have been assigned to the United States of America. The prospective license will be royalty-bearing, will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7, and is expected to be co-exclusive with one other party, COR Therapeutics, Inc. It is anticipated that this license will be limited to gene therapy treatment of cardiovascular disease. Publication of this notice should be considered a modification of an earlier notice ``Prospective Grant of Exclusive License: Type Alpha Platelet-Derived Growth Factor'' (Vol. 58, No. 16, Wednesday, January 17, 1993, page 6287). This prospective co-exclusive license may be granted unless, within 60 days from the date of this published notic